- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02990715
Evaluation of Check-Cap C-Scan System in Providing Structural Information and Detection of Polypoid Lesions
Study Overview
Detailed Description
The subject will be invited to come to the clinic to sign the ICF and other related documents. Then they'll ingest the capsule typically during the morning hours. The subjects will be connected to the C-Scan Track and system's activation the subject will be asked to ingest the C-Scan Capsule with some water and contrast media, in the presence of a physician.
Post ingestion, the subject will be discharged home with clear instructions on the procedure. The subject should avoid intensive physical exercise during procedure or any extreme activities. The subject should make an effort to stay at home or other familiar surroundings, and may continue daily activities such mobile/computer/TV use, shower, sleep or eat. Details on allowed and restricted activities are listed in app. 4 The subject will be required to ingest daily dose (3 X 15-17ml) of contrast media, to be consumed three times per day with normal diet. Also on a need based the subject would be provided with laxadine (5 mg tablets) to be ingested according to the doctor recommendation.
During capsule procedure the subjects will be contacted by phone several times daily by the site clinical study team (or by dedicated external trained medical personnel), to assure the subjects well-being and to monitor for any change or discomfort and for procedure progress. Subjects may be also monitored by the technical team (either at home or at the clinic), who may need to examine the system or inquire the subjects about the system visual/auditory indicators.
The subjects will be provided with a dedicated capsule collection kit, to assist the subjects in collecting the capsule. Subjects will be instructed to retrieve the capsule upon excretion.
Capsule procedure is completed upon capsule excretion or system vibro/auditory indication of 'End of Procedure'.
Patients will be instructed to return the C-Scan Capsule and C-Scan Track to the clinic for analysis.
All subjects will be scheduled for optical colonoscopy to be performed within one month following capsule procedure.
C-Scan Procedure Analysis:
Two to three licensed gastroenterologist physicians, will be trained with reviewing and analyzing C-Scan System scans, to serve as independent reviewers. A reviewing forum consisting of at least one independent trained gastroenterologist physician and at least 2 expert Check-Cap reviewers that will jointly review all the cases. The reviewing forum will be blinded to the FIT and colonoscopy results of the examined patients..). Analysis will be performed on a per patient basis for the existence or non-existence of a finding that may be a polyp. This per patient finding will be compared with the FIT, and a colonoscopy will be performed for verification.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tel Aviv, Israel, 64000
- Sourasky Medical Center
-
-
Galilee
-
'Afula, Galilee, Israel
- Emek Medical Center
-
-
North
-
Haifa, North, Israel
- Rambam Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female at the age of 30-80 years old
- Subject provided signed informed consent
Exclusion Criteria:
- Patients with advanced cancer or other life threatening diseases or conditions
- Subject with known history of dysphagia or other swallowing disorders
- Subject with known history of GI disease or symptoms, such as: Crohn's disease, Colitis, IBD, Meckel's Diverticulum, Bowen Hernia, Mega Colon, fistulas or other strictures (doctors' discretion).
- Subject with known motility disorder or Chronic Constipation
- Subject with known delayed gastric emptying
- Subject with prior history of abdominal surgery that might cause bowel strictures leading to capsule retention, as determined by physician discretion
- Subject with any condition believed to have an increased risk for capsule retention such as intestinal tumors, radiation enteritis, and incomplete colonoscopies due to obstructions or NSAID enteropathy, as determined by physician discretion
- Subject with a cardiac pacemaker or other implanted electro medical device
- Subjects with known sensitivity to iodine, or with kidney failure
- Subjects with morbid obesity (BMI > 40)
- Subject with any known condition which precludes compliance with study and/or device instructions
- Subject with known condition of drug abuse and/or alcoholism
- Subject who is unable to undergo colonoscopy or bowel preparation necessary for colonoscopy (based on previous attempts or self-declaration)
- Women who are either pregnant or nursing at the time of screening (to be verified by test in case of woman of child-bearing potential that do not practice medically acceptable methods of contraception)
- Concurrent participation in another clinical trial using any investigational drug or device
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Up to 45 subjects
Subjects with known polyp lesions≥10mm which were not removed because of poor preperation or the need to perform polypectomy at hospital will ingest the C-Scan cap and then will be schduled to polypectomy.
The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
|
Other Names:
|
|
Experimental: Up to 25 subjects
Subjects who were reffered to screening colonoscopy as an average risk for CRC will ingest the C-Scan cap and then will be schduled to polypectomy.
The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity and specificity of C-Scan Capsule System in detecting per segment polypoid lesions 10 mm and up as compared with Colonoscopy
Time Frame: One year
|
Number of polyps detected by the capsulle system in variuos segements of the colon as compared with the results indicated in the report of the follow-up colonoscopy
|
One year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity and specificity of C-Scan Capsule System in detecting patients with polypoid lesions 6≤x≤9 mm, compared with Optical Colonoscopy
Time Frame: One year
|
Number of polyp specificity of C-Scan Capsule System in detecting patients with polypoid lesions 6≤x≤9 mm detected by the capsule system in variuos segements of the colon as
|
One year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Alex Ovadia, COO, VP R&D
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CL-SY-01-0093
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polypoid Lesions
-
Chengdu Kanghong Biotech Co., Ltd.UnknownPolypoid Choroidal Vasculopathy (PCV)China
-
Cynosure, Inc.CompletedBenign Pigmented Lesions | Wrinkle | Benign Vascular LesionsUnited States
-
Rigshospitalet, DenmarkCompletedFocal Liver Lesions | Focal Lesions in the AbdomenDenmark
-
Salutaris Medical Devices, Inc.Not yet recruitingAge-Related Macular Degeneration | Polypoid Choroidal Vasculopathy
-
Orthopaedic Research FoundationGenzyme, a Sanofi CompanyCompletedChondrosis | Patellar Articular Cartilage Lesions | Trochlear Articular Cartilage LesionsUnited States
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Sohag UniversityRecruitingEsophageal LesionsEgypt
-
M.D. Anderson Cancer CenterNational Institute of Dental and Craniofacial Research (NIDCR)Recruiting
-
Cairo UniversityNot yet recruiting
-
The First Affiliated Hospital of Xiamen UniversityCompleted
Clinical Trials on C-Scan System
-
Check-Cap Ltd.CompletedRisk for Colorectal CancerIsrael
-
Check-Cap Ltd.Completed
-
Check-Cap Ltd.RecruitingHealthy SubjectsIsrael
-
Check-Cap Ltd.TerminatedHealthyUnited States
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical CenterCompletedProstate CancerUnited States
-
Check-Cap Ltd.CompletedHigh Risk (Above Average) Subjects | Non Compliant Patients for Colo Rectal Cancer [CRC] Screening | Counterindicated Patients for ColonoscopyIsrael
-
The Cleveland ClinicSiemens Medical SolutionsCompleted
-
Rajesh NarendranNational Institute on Drug Abuse (NIDA)Recruiting
-
Rigshospitalet, DenmarkUnknown
-
Cardica, IncCompletedHeart DiseaseUnited States